I 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The  company  Orion  Pharma  A/S  (Europharm  A/S),  Denmark,  submitted  on  4  April  1997  to  the 
European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA),  an  application  for  Marketing 
Authorisation  for  the  medicinal  product  Comtan  tablets  200  mg  in  accordance  with  the  Centralised 
Procedure falling within the scope of Part B of the Annex to Council Regulation No (EC) 2309/93 of 
22 July 1993. On 19 December 1997, the application was transferred to Novartis Europharm Limited, 
United Kingdom. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Dr. E. Alhava 
Co-Rapporteur: 
Mrs. J. Genoux-Hames 
Licensing status 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 April 1997. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 26 June 1997. 
The Co-Rapporteur’s first assessment report was circulated to all CPMP Members on 27 June 
1997. 
During the June 1997 CPMP meeting, it was agreed to perform a GMP inspection on the Swiss 
manufacturing facilities for the finished medicinal product. 
During  the  CPMP  plenary  meeting  on  23  September  1997,  the  CPMP  agreed  on  the 
consolidated list of questions to be sent to the company. The final consolidated list of questions 
was sent to the Company on 23 September 1997.  
The company submitted the responses to the consolidated list of questions on 6 February 1998. 
The  Rapporteur/Co-Rapporteur  circulated  the  joint  assessment  report  on  the  company’s 
responses to the list of questions to all CPMP Members on 27 March 1998. 
A  hearing  was  held  on  26  May  1998,  at  the  CPMP  meeting  to  address  the  remaining 
outstanding  issues.  This  resulted  in  amendments  of  the  Summary  of  Product  Characteristics, 
Package Leaflet and Labelling. 
The CPMP, during its  meeting  on 26 May 1998  discussed the recommendations presented by 
the  Rapporteur,  considering  the  responses  provided  by  the  company  were  satisfactory. 
Amendments  were  discussed  to  the  Summary  of  Product  Characteristics  and  Package  Leaflet 
texts. 
The CPMP during its May meeting, issued by majority a positive opinion (17 out of 24 CPMP 
members, no abstention) for granting a Marketing Authorisation to Comtan 200 mg film coated 
tablets, on 27 May 1998. 
The  CPMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 22 September 1998. 
1/1 

EMEA 2004 
 
 
 
 
 
 
 
 
